Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093646780> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2093646780 endingPage "68" @default.
- W2093646780 startingPage "55" @default.
- W2093646780 abstract "Highly active antiretroviral therapy has resulted in a dramatic decline in morbidity and mortality among patients infected with HIV. Nevertheless, this success has to be considered in the context of the current challenges and needs in this field. Adherence, toxicity, potency and resistance are still matters of intense research, which need to improve in order to overcome the current limitations of available drugs. Regarding needs, the improvement of convenience, tolerability and pharmacokinetics run in parallel with toxicity reduction, improvement of activity (both for wild-type and resistant virus), penetration into viral reservoirs and exploitation of new targets. The Food and Drug Administration approved emtricitabine in July 2003 for use in combination with other antiretroviral agents in adults with HIV-1 infection. Approval was based on the results of two Phase III clinical trials. The first was a double-blind study comparing the safety and efficacy of emtricitabine + didanosine + efavirenz to stavudine + didanosine + efavirenz as initial treatment in individuals who had not previously received antiretroviral therapy. At 24 and 48 weeks, patients receiving emtricitabine had significantly higher rates of virological suppression and greater increases in CD4+ counts than stavudine recipients. The second study was an open-label trial in treatment-experienced patients with HIV RNA < 400 copies/ml on a lamivudine-containing regimen in combination with either stavudine or zidovudine and either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor for at least 12 weeks. Patients were randomised either to continue lamivudine (150 mg b.i.d.) or to switch to emtricitabine 200 mg o.d. while maintaining the same background medications. In this study, the proportion of patients whose viral loads remained suppressed at the < 400 and < 50 copies/ml levels were similar in the two treatment groups. Potency, tolerability, convenient dosing and a low rate of side effects are some of the main characteristics of this new drug." @default.
- W2093646780 created "2016-06-24" @default.
- W2093646780 creator A5061097917 @default.
- W2093646780 date "2004-01-01" @default.
- W2093646780 modified "2023-09-23" @default.
- W2093646780 title "Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy" @default.
- W2093646780 cites W1968993671 @default.
- W2093646780 cites W2002085166 @default.
- W2093646780 cites W2003199949 @default.
- W2093646780 cites W2004293828 @default.
- W2093646780 cites W2018551422 @default.
- W2093646780 cites W2022188917 @default.
- W2093646780 cites W2033675160 @default.
- W2093646780 cites W2066825319 @default.
- W2093646780 cites W2095709318 @default.
- W2093646780 cites W2096555443 @default.
- W2093646780 cites W2109763529 @default.
- W2093646780 cites W2115627428 @default.
- W2093646780 cites W2116382218 @default.
- W2093646780 cites W2118047663 @default.
- W2093646780 cites W2119423984 @default.
- W2093646780 cites W2164099498 @default.
- W2093646780 cites W2166670196 @default.
- W2093646780 cites W2171909957 @default.
- W2093646780 cites W2318289184 @default.
- W2093646780 cites W4206096711 @default.
- W2093646780 doi "https://doi.org/10.1517/13543784.13.1.55" @default.
- W2093646780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14680453" @default.
- W2093646780 hasPublicationYear "2004" @default.
- W2093646780 type Work @default.
- W2093646780 sameAs 2093646780 @default.
- W2093646780 citedByCount "18" @default.
- W2093646780 countsByYear W20936467802012 @default.
- W2093646780 countsByYear W20936467802013 @default.
- W2093646780 countsByYear W20936467802016 @default.
- W2093646780 countsByYear W20936467802017 @default.
- W2093646780 countsByYear W20936467802020 @default.
- W2093646780 countsByYear W20936467802023 @default.
- W2093646780 crossrefType "journal-article" @default.
- W2093646780 hasAuthorship W2093646780A5061097917 @default.
- W2093646780 hasConcept C126322002 @default.
- W2093646780 hasConcept C142462285 @default.
- W2093646780 hasConcept C159047783 @default.
- W2093646780 hasConcept C197934379 @default.
- W2093646780 hasConcept C2522874641 @default.
- W2093646780 hasConcept C2777351918 @default.
- W2093646780 hasConcept C2777447569 @default.
- W2093646780 hasConcept C2777869810 @default.
- W2093646780 hasConcept C2778375690 @default.
- W2093646780 hasConcept C2779778239 @default.
- W2093646780 hasConcept C2779889181 @default.
- W2093646780 hasConcept C2780216070 @default.
- W2093646780 hasConcept C2780593183 @default.
- W2093646780 hasConcept C2780727368 @default.
- W2093646780 hasConcept C2781432083 @default.
- W2093646780 hasConcept C2993143319 @default.
- W2093646780 hasConcept C3013748606 @default.
- W2093646780 hasConcept C71924100 @default.
- W2093646780 hasConcept C98274493 @default.
- W2093646780 hasConceptScore W2093646780C126322002 @default.
- W2093646780 hasConceptScore W2093646780C142462285 @default.
- W2093646780 hasConceptScore W2093646780C159047783 @default.
- W2093646780 hasConceptScore W2093646780C197934379 @default.
- W2093646780 hasConceptScore W2093646780C2522874641 @default.
- W2093646780 hasConceptScore W2093646780C2777351918 @default.
- W2093646780 hasConceptScore W2093646780C2777447569 @default.
- W2093646780 hasConceptScore W2093646780C2777869810 @default.
- W2093646780 hasConceptScore W2093646780C2778375690 @default.
- W2093646780 hasConceptScore W2093646780C2779778239 @default.
- W2093646780 hasConceptScore W2093646780C2779889181 @default.
- W2093646780 hasConceptScore W2093646780C2780216070 @default.
- W2093646780 hasConceptScore W2093646780C2780593183 @default.
- W2093646780 hasConceptScore W2093646780C2780727368 @default.
- W2093646780 hasConceptScore W2093646780C2781432083 @default.
- W2093646780 hasConceptScore W2093646780C2993143319 @default.
- W2093646780 hasConceptScore W2093646780C3013748606 @default.
- W2093646780 hasConceptScore W2093646780C71924100 @default.
- W2093646780 hasConceptScore W2093646780C98274493 @default.
- W2093646780 hasIssue "1" @default.
- W2093646780 hasLocation W20936467801 @default.
- W2093646780 hasLocation W20936467802 @default.
- W2093646780 hasOpenAccess W2093646780 @default.
- W2093646780 hasPrimaryLocation W20936467801 @default.
- W2093646780 hasRelatedWork W1496223852 @default.
- W2093646780 hasRelatedWork W1545921990 @default.
- W2093646780 hasRelatedWork W2033418767 @default.
- W2093646780 hasRelatedWork W2068616862 @default.
- W2093646780 hasRelatedWork W2093646780 @default.
- W2093646780 hasRelatedWork W2096675880 @default.
- W2093646780 hasRelatedWork W2184839335 @default.
- W2093646780 hasRelatedWork W2405408997 @default.
- W2093646780 hasRelatedWork W3027176954 @default.
- W2093646780 hasRelatedWork W4299397867 @default.
- W2093646780 hasVolume "13" @default.
- W2093646780 isParatext "false" @default.
- W2093646780 isRetracted "false" @default.
- W2093646780 magId "2093646780" @default.
- W2093646780 workType "article" @default.